Evaluate SARS-CoV2 infection and the degree of immunity possibly developed in transplanted population using the Luciferase Immuno Precipitation System (LIPS) test.
Study Type
OBSERVATIONAL
Enrollment
282
blood sample for seroepidemiological investigation
IRCCS San Raffaele
Milan, Italy
Serum-prevalence of COVID-19 TX
Evaluation of serum-prevalence data transplanted patients (symptomatic vs asymptomatic patients)
Time frame: From 15 July 2020 to 15 January 2021
Serum-prevalence of COVID-19 / Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients
Correlation serum-prevalence of COVID-19 / Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients
Time frame: From 15 July 2020 to 15 January 2021
Asymptomatic or subclinical infections in transplanted patients
Determine % Asymptomatic or subclinical infections in transplanted patients
Time frame: From 15 July 2020 to 15 January 2021
Risk factors for infection COVID-19 transplanted patients
Determine risk factors for infection COVID-19 (comparison symtomatic and asymtomatic transplanted patients)
Time frame: From 15 July 2020 to 15 January 2021
Hospitalization rate COVID-19 transplanted patients
Evaluate hospitalization rate in transplanted patients
Time frame: From 15 July 2020 to 15 January 2021
Mortality rate COVID-19 transplanted patients
Evaluate mortality rate in transplanted patients
Time frame: From 15 July 2020 to 15 January 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.